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Introduction
Metastatic osteolytic disease is prevalent in cancer patients. In advanced breast cancer (BrCa), 70% of women develop osteolytic lesions, resulting in pain, pathologic fracture, and increased morbidity. Dysfunction of the ubiquitin-proteasome system is associated with tumor growth and metastatic disease, providing the rationale for development of proteasome inhibitors as antineoplastic therapies [1, 2] . The proteasome is a ubiquitous enzyme complex that plays a critical role in the degradation of proteins involved in cell cycle regulation, apoptosis, and angiogenesis [2, 3] . Bortezomib (Bzb), a selective proteasome inhibitor used to treat multiple myeloma, has a potent anabolic effect on bone [4] [5] [6] [7] [8] [9] . Bzb alters the bone marrow microenvironment by increasing the number and differentiation of resident mesenchymal stem cells (MSC) into osteoblasts, thereby increasing bone-formation rates within 4 weeks in normal mice and resulting in trabecular bone formation in bone loss model [7] . A similar enhancement of osteoblast-differentiation is found in myeloma patients treated with Bzb who show sustained increases in circulating osteocalcin, a marker of bone formation [6, 10] . Thus, Bzb treatment represents a novel and clinically feasible approach for increasing bone formation in the setting of the osteolytic bone disease accompanying metastatic breast, prostate, and lung cancers [4, 5, 11] .
Nonsurgical treatment of bone metastatic lesions includes radiation therapy and bisphosphonates. Bisphosphonates were initially reported to reduce the risk of pathologic fracture and bone pain, although a recent study totaling over 7000 BrCa patients indicated no reduction in fracture risk as compared to placebo or no treatment groups [12] [13] [14] . In addition, bisphosphonates at doses required for cancer patients can have a significant side effect profile [15, 16] and alternate approaches to protect the skeleton are needed.
Tumor cells in the bone microenvironment overcome the marrow compartment and inhibit the ability of sufficient stromal cells to differentiate into osteoblasts to replace lost bone.
Cancer cells secrete factors that induce a vicious cycle of osteoclast activation and growth factor release that promotes tumor survival. Bzb contributes to the apoptosis of tumor cells and tumoractivated osteoclasts [17] [18] [19] ; as well, low dose Bzb promotes bone anabolic effects in mice [7] .
forward, TCTTCAAGCCATCCTGTGTG, reverse, GCGAGTCTGTGTTTTTGCAG. Real-time PCR analysis was performed to confirm expression levels by using an ABI machine and PRISM software (Applied Biosystems, Carlsbad CA); significant differences were determined by Student's t-test. 
Annexin

Results
Bortezomib slows the growth of osteolytic lesions caused by BrCa tumors in the bone microenvironment
Given the anabolic effects of Bzb on bone in multiple myeloma, we investigated if Bzb treatment could ameliorate the osteolysis caused by breast cancer cells in bone. Mice that received intra-tibial inoculations of MDA-MB-231 BrCa cells were treated with 0.3 mg/kg body weight Bzb administered 3 times a week for 7 weeks. This dose and schedule represents the highest Bzb dose used in a study in which the serum osteocalcin level, a marker of bone formation, was found to increase in response to Bzb treatment [7] . We observed this dose to be non-toxic throughout the duration of the study (n>24 mice). Figure 1A reduced bone loss in the region of the tumor cell inoculation when compared to control treated mice. These conclusions are in part based on a semi-quantitative evaluation of the radiographs based on a scoring system (see methods) (Fig. 1B ). An aggressive increase in osteolysis was observed in controls after day 28 when tumor destroyed the cortical bone, invaded the surrounding tissue and contributed to osteolysis from the periosteal side of bone as well as from the medullary cavity. In the Bzb group, a clear inhibition of osteolytic disease is delayed until 4-5 weeks. After this point, low levels of osteolytic activity occurred indicated by the appearance of lesions at the end of the study (Fig. 1A) . A similar late appearance of osteolytic lesions was observed in different experiments (data not shown).
Radiographs in
The tumor containing tibias were further analyzed by ex vivo micro computed tomography (micro-CT) in n=3 mice. Figure 1C shows tibias of control mice with extensive osteolytic disease eroding through the cortex, while the tibias of the Bzb treated mice had minimal evidence of cortical erosion and mild osteolysis. Quantitative analysis by micro-CT shows that the tumor bearing tibias of the Bzb treated mice have greater than 2-fold higher bone volume than the tibias of control mice (Fig. 1D) . Taken together, these findings show that the Bzb treated mice had a striking inhibition of osteolytic disease.
Bortezomib reduces the size of BrCa tumors
The volume of intra-tibial BrCa tumors was measured in vivo in Bzb and control treated mice by injecting the mice with 
Treatment with Bortezomib prior to tumor cell inoculation protects bone from osteolysis
To assess clinical relevance, a study was designed to establish if Bzb given prior to tumor metastasis decreased tumor growth and osteolytic disease and would protect the bone from subsequent osteolysis. Therefore, we examined Bzb treatment of mice for a period of time prior to the intra-tibial inoculation of MDA-MB-231 cells. The rationale was twofold. First, the anabolic effect that Bzb treatment has on bone might render the bone less susceptible to subsequent osteolysis. Second, this has translational relevance as Bzb treatment might be used prophylactically to decrease the likelihood of BrCa patients developing osteolytic lesions. The study consisted of three groups: mice that were not treated prior to or following tumor cell inoculation, mice that were treated with Bzb (0.3 mg/kg body weight IP 3 times a week) both before and after tumor inoculation, and mice that were treated with Bzb only before, but not after injection of tumor cells (Bzb pretreatment) ( tumor tissue, RANKL, promoting bone resorption, was stimulated. This finding reflects the histological analyses of the Bzb treated group (see Fig. 2D ) exhibiting osteoclastic activity.
We conclude from these studies that metastasis associated osteolytic disease is reduced in vivo by Bzb through multiple mechanisms in the bone microenvironment: by inducing cellular necrosis, decreasing the tumor response to Wnt signaling, reducing expression of a key factor in tumor vascularization, and decreasing the Runx2 and MMP-9 osteolytic cascade. Together, these modifications in tumor cell activity by Bzb contribute to inhibiting tumor growth to the bone microenvironment.
Discussion
Here we established that the proteasome inhibitor Bzb effectively suppresses BrCa tumor growth within bone, and stimulates new bone formation in the presence of metastatic disease.
Anti-tumor growth effects by Bzb occur in the bone microenvironment where the vicious cycle of tumor growth and osteolytic disease is activated in response to BrCa cells. We show that the anti-osteolytic effects of Bzb are primarily due to significantly decreased tumor size as evidenced by histology, radiographic monitoring and micro-CT quantitation of bone volume.
Lastly, we have defined mechanisms contributing to the inhibition of tumor growth in the bone microenvironment and osteolytic disease by Bzb that include (i) the sensitivity of highly metastatic breast cancer cells to necrosis, (ii) reduction in expression of metastatic and tumor growth related genes, and (iii) promotion of bone formation throughout the skeleton. These effects of Bzb provide a beneficial anti-tumor and bone anabolic effect.
In our continuously treated study, we find a striking inhibition of osteolytic disease that continued through 4 weeks post inoculation. However, at 5 weeks evidence of the onset of osteolysis was identified in the Bzb group, which slowly progressed until the study was terminated when tumor size became unbearable in the control group (7 or 8 weeks in repeat study). The Ki67 assays suggest that surviving tumor cells exposed to Bzb results in a delayed Early studies found mixed results in ongoing clinical trials evaluating the effect of Bzb on osteolytic lesions caused by solid tumors [34] [35] [36] [37] . However, in one other study using the intratibial model of prostate cancer, it was suggested that osteoclast activity was diminished [38] , similar to what has been shown in multiple myeloma patients [39] . In our studies, the net effect of systemic Bzb is that proteasome inhibition is effective in preventing BrCa tumor growth in bone and greatly diminishes the osteolytic disease. Thus, just as Bzb is used for multiple myeloma cells which have increased proteasome activity [40] inducing osteolytic bone disease (as does breast cancer [18] ), we find Bzb has the similar anti-osteolytic effects in BrCa tumors.
We identified mechanisms that are directly attributed to Bzb modifying the properties of BrCa cells in vivo to facilitate an anabolic effect in the bone microenvironment in the presence of a tumor. Analysis of the tumor tissue revealed a reduction in the metastasis related genes Runx2, VEGF and MMP9 at high doses of Bzb. This profile reflects altered cellular properties, reduced tumor vascularization, migration, matrix destruction, and osteolytic disease [27, 30, [41] [42] [43] [44] .
Another mechanism of Bzb inhibiting tumor growth is by elevation of DKK1, an inhibitor of the Wnt signaling pathway, and a concomitant decrease in Lef-1, the transcriptional mediator of Wnt signaling, thereby decreasing tumor growth potential. In multiple myeloma patients, serum levels of DKK are very low, contributing to activated Wnt signaling [21, 22] . BrCa tumorigenesis and bone metastasis are linked to the Wnt signaling pathway, having downregulated DKK and dysregulation of β-catenin linked to progression and prognosis [31, 45- Our studies are significant as the anabolic effects of Bzb on BrCa-free bone in the setting of metastatic bone disease were demonstrated by a 1.5 fold increase in bone volume.
Furthermore, we showed that the effects of a 3 week pre-treatment allowed accrual of bone throughout the skeleton from the analyses of the non-tumor bearing femurs. This suggests a preemptive, protective effect to the bone, thereby diminishing the effect of tumor mediated osteolysis. Thus we find an additional benefit to the anabolic bone effect, as pretreatment with Bzb has a repressive effect on subsequent tumor growth. The clinical implications of these results are considerable. Proteasome inhibitors could provide a protective effect on the skeleton if Bzb were to be combined with other treatments for BrCa prior to metastasis.
In summary, proteasome inhibitors may treat solid tumors and the osteolytic bone disease that accompanies metastasis by myriad effects that include: decreasing tumor cell proliferation and survival, inhibiting bone destructive pathways and enzymes and vascularity of the tumors, reducing osteoclast number and function [17, 24, 25, 39] , and increasing osteoblast differentiation and bone formation [7, 9, 22, 33] . Our studies demonstrate inhibitory effects of Bzb on solid tumor (breast cancer) growth in bone and prevention of the early onset osteolytic disease. We conclude that proteasome inhibitors have multifactorial beneficial effects in prevention of BrCa growth in bone and induced osteolysis. 
